Oct. 9 at 5:33 PM
Cue Biopharma shares rose Thursday, extending recent gains after the 2025 Nobel Prize in Physiology or Medicine recognized breakthroughs in immune regulation that align closely with the company’s CUE-401 development program.
The Nobel was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries in peripheral immune tolerance and regulatory T cells (Tregs), validating the scientific foundation of Cue’s approach to treating autoimmune diseases.
CUE-401 uses a dual IL-2/TGF-β mechanism designed to restore immune balance by expanding Tregs while suppressing pathogenic effector cells. Preclinical data have shown that the molecule can induce potent and stable Tregs, suggesting broad potential across multiple autoimmune indications.
$CUE